FTC Tells Medtronic To Sell Intersect ENT Subsidiary To Avoid Monopoly
The move removes all regulatory roadblocks to Medtronic’s $1.1bn acquisition of Intersect ENT, which was announced in August 2021.
You may also be interested in...
Dexcom may be planning to purchase Insulet to enter the insulin pump market and transform itself into a diabetes tech giant.
Medtronic announced plans to acquire Intersect ENT, adding its sinus implants to Medtronic's portfolio of devices used by surgeons in treating chronic rhinosinusitis.
It was a quiet month for warning letters at the FDA last month, with the agency issuing no new warning letters and closing out only one.